High-risk prostate cancer: From definition to contemporary management

European Urology

Volumn 61, Issue 6, 2012, Pages 1096-1106

  Bastian, Patrick J ^a   Boorjian, Stephen A ^b   Bossi, Alberto ^c   Briganti, Alberto ^d   Heidenreich, Axel ^e   Freedland, Stephen J ^f   Montorsi, Francesco ^d   Roach III, MacK ^g   Schröder, Fritz ^h   Van Poppel, Hein ⁱ   Stief, Christian G ^a   Stephenson, Andrew J ^j   Zelefsky, Michael J ^k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f DUKE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j LERNER RESEARCH INSTITUTE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Adjuvant therapy; Androgen deprivation therapy; Biomarker; High risk prostate cancer; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DISEASE SPECIFIC SURVIVAL; EMBASE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; LOW RISK PATIENT; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDICAL LITERATURE; MEDLINE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; LYMPH NODE EXCISION; MALE; NEOADJUVANT THERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860281050     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.02.031     Document Type: Review

References (112)

1. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
2. C. Bosetti, P. Bertuccio, L. Chatenoud, E. Negri, C. La Vecchia, and F. Levi Trends in mortality from urologic cancers in Europe, 1970-2008 Eur Urol 60 2011 1 15
3. T.A. Stamey, and J.N. Kabalin Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, I: untreated patients J Urol 141 1989 1070 1075 (Pubitemid 19124200)
4. T.A. Stamey, J.N. Kabalin, and M. Ferrari Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, III: radiation treated patients J Urol 141 1989 1084 1087 (Pubitemid 19124202)
5. T.A. Stamey, J.N. Kabalin, and J.E. McNeal Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients J Urol 141 1989 1076 1083 (Pubitemid 19124201)
6. G.K. Zagars Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy Int J Radiat Oncol Biol Phys 23 1992 47 53
7. G.K. Zagars, A. Pollack, and A.C. von Eschenbach Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen Int J Radiat Oncol Biol Phys 33 1995 23 35
8. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
9. M.W. Kattan, J.A. Eastham, A.M. Stapleton, T.M. Wheeler, and P.T. Scardino A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771 (Pubitemid 28259189)
10. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131 (Pubitemid 46726449)
11. M. Umbehr, L.M. Bachmann, and U. Held Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis Eur Urol 55 2009 575 591
12. M. Seitz, A. Shukla-Dave, and A. Bjartell Functional magnetic resonance imaging in prostate cancer Eur Urol 55 2009 801 814
13. L. Gerber, L.L. Bañez, and S.J. Freedland Defining and treating high-risk prostate cancer: can we do better? Eur Urol 58 2010 8 9
14. L. Dickinson, H.U. Ahmed, and C. Allen Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting Eur Urol 59 2011 477 494
15. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
16. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80 (Pubitemid 350166735)
17. H. Van Poppel, and S. Joniau An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer Eur Urol 53 2008 253 259 (Pubitemid 350296585)
18. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
19. M. Roach, J. Lu, and M.V. Pilepich Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials Int J Radiat Oncol Biol Phys 47 2000 609 615 (Pubitemid 30317478)
20. M. Roach III, V. Weinberg, M. Nash, H.M. Sandler, P.W. McLaughlin, and M.W. Kattan Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials J Urol 176 2006 S16 S20
21. Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol;7:31-8.
22. S.A. Rosenthal, K. Bae, and K.J. Pienta Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02 Int J Radiat Oncol Biol Phys 73 2009 672 678
23. M.R. Cooperberg, D.J. Pasta, and E.P. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942 (Pubitemid 40675216)
24. S.K. Bechis, P.R. Carroll, and M.R. Cooperberg Impact of age at diagnosis on prostate cancer treatment and survival J Clin Oncol 29 2011 235 241
25. C.T. Nguyen, A.M. Reuther, A.J. Stephenson, E.A. Klein, and J.S. Jones The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival J Urol 181 2009 75 80
26. M.R. Cooperberg, J.F. Hilton, and P.R. Carroll The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy Cancer 117 2011 5039 5046
27. M. Roach III, F. Waldman, and A. Pollack Predictive models in external beam radiotherapy for clinically localized prostate cancer Cancer 115 2009 3112 3120
28. P.J. Bastian, G.S. Palapattu, and S. Yegnasubramanian CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer J Urol 179 2008 529 534 discussion 534-5
29. P.J. Bastian, G.S. Palapattu, and S. Yegnasubramanian Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy Clin Cancer Res 13 2007 5361 5367 (Pubitemid 47510361)
30. P.J. Bastian, G.S. Palapattu, and X. Lin Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy Clin Cancer Res 11 2005 4037 4043 (Pubitemid 40791567)
31. W.G. Nelson, A.M. De Marzo, and S. Yegnasubramanian Epigenetic alterations in human prostate cancers Endocrinology 150 2009 3991 4002
32. A.W. Partin, B.R. Lee, M. Carmichael, P.C. Walsh, and J.I. Epstein Radical prostatectomy for high grade disease: a reevaluation 1994 J Urol 151 1994 1583 1586 (Pubitemid 24151308)
33. C.J. Kane, J.C. Presti Jr., C.L. Amling, W.J. Aronson, M.K. Terris, and S.J. Freedland Changing nature of high risk patients undergoing radical prostatectomy J Urol 177 2007 113 117 (Pubitemid 44895334)
34. S.A. Boorjian, R.J. Karnes, L.J. Rangel, E.J. Bergstralh, I. Frank, and M.L. Blute Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers BJU Int 101 2008 299 304
35. P.J. Bastian, M.L. Gonzalgo, and W.J. Aronson Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative GS of 8 to 10 Cancer 107 2006 1265 1272 (Pubitemid 44452775)
36. A.J. Stephenson, M.W. Kattan, and J.A. Eastham Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol 27 2009 4300 4305
37. C.G. Rogers, M.A. Khan, M. Craig Miller, R.W. Veltri, and A.W. Partin Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy Cancer 101 2004 2549 2556 (Pubitemid 39532284)
38. S.E. Eggener, P.T. Scardino, and P.C. Walsh Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
39. O. Yossepowitch, S.E. Eggener, and A.M. Serio Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Eur Urol 53 2008 950 959 (Pubitemid 351434496)
40. O. Yossepowitch, S.E. Eggener, and F.J. Bianco Jr. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499 discussion 499 (Pubitemid 47030486)
41. U. Zwergel, H. Suttmann, and T. Schroeder Outcome of prostate cancer patients with initial PSA ≥ 20 ng/ml undergoing radical prostatectomy Eur Urol 52 2007 1058 1066 (Pubitemid 47337032)
42. M. Spahn, S. Joniau, and P. Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients Eur Urol 58 2010 1 7 discussion 10-1
43. S.J. Freedland, A.W. Partin, E.B. Humphreys, L.A. Mangold, and P.C. Walsh Radical prostatectomy for clinical stage T3a disease Cancer 109 2007 1273 1278 (Pubitemid 46466553)
44. C.-Y. Hsu, S. Joniau, R. Oyen, T. Roskams, and H. Van Poppel Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience Eur Urol 51 2007 121 129 discussion 128-9 (Pubitemid 44821509)
45. B.A. Inman, J.D. Davies, and L.J. Rangel Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥50 ng/mL Cancer 113 2008 1544 1551
46. S. Joniau, C.-Y. Hsu, and E. Lerut A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer Eur Urol 51 2007 388 396 discussion 395-6 (Pubitemid 44937792)
47. P. Gontero, S. Joniau, and H. Van Poppel Radical prostatectomy for PSA ≥100 ng/ml prostate cancer Eur Urol 54 2008 957 958
48. K. Nguyen, S. Eltz, and S.J. Drouin Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience World J Urol 27 2009 653 658
49. J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, and H. Zincke Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756 (Pubitemid 40547200)
50. A. Briganti, F.K.-H. Chun, and A. Salonia Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer Eur Urol 50 2006 1006 1013 (Pubitemid 44486500)
51. A. Mattei, F.G. Fuechsel, and N. Bhatta Dhar The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study Eur Urol 53 2008 118 125 (Pubitemid 350166722)
52. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis J Urol 167 2002 1681 1686 (Pubitemid 34240702)
53. P. Bader, F.C. Burkhard, R. Markwalder, and U.E. Studer Disease progression and survival of patients with positive lymph nodes after radical prostatectomy: is there a chance of cure? J Urol 169 2003 849 854 (Pubitemid 36188105)
54. A. Fleischmann, S. Schobinger, and R. Markwalder Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival Histopathology 53 2008 468 475
55. A. Fleischmann, S. Schobinger, M. Schumacher, G.N. Thalmann, and U.E. Studer Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases Prostate 69 2009 352 362
56. A. Briganti, M.L. Blute, and J.H. Eastham Pelvic lymph node dissection in prostate cancer Eur Urol 55 2009 1251 1265
57. M.C. Schumacher, F.C. Burkhard, G.N. Thalmann, A. Fleischmann, and U.E. Studer Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344 352
58. J. Engel, P.J. Bastian, and H. Baur Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
59. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
60. U.E. Studer, L. Collette, and R. Sylvester Can radical prostatectomy benefit patients despite the presence of regional metastases? Eur Urol 57 2010 762 763 author reply 763-5
61. T. Steuber, L. Budaus, and J. Walz Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study BJU Int 107 2011 1755 1761
62. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
63. S. Kumar, M. Shelley, C. Harrison, B. Coles, T.J. Wilt, and M.D. Mason Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
64. H. Isbarn, L. Boccon-Gibod, and P.R. Carroll Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Eur Urol 55 2009 62 75
65. M. Wirth, C. Tyrrell, and K. Delaere Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up Prostate Cancer Prostatic Dis 10 2007 87 93 (Pubitemid 46358917)
66. S.A. Siddiqui, S.A. Boorjian, B. Inman, S. Bagniewski, E.J. Bergstralh, and M.L. Blute Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study J Urol 179 2008 1830 1837 discussion 1837
67. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
68. E.M. Messing, J. Manola, and J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479 (Pubitemid 43779173)
69. S.A. Boorjian, R.H. Thompson, and S. Siddiqui Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 178 2007 864 870 discussion 870-1
70. J.W. Moul, H. Wu, and L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147 (Pubitemid 38327544)
71. A.S. Kibel, E. Rosenbaum, and M.W. Kattan Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study J Urol 177 2007 1777 1781 (Pubitemid 46560677)
72. W.Y. Kim, Y.E. Whang, and R.S. Pruthi Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial Urol Oncol 29 2011 608 613
73. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946 (Pubitemid 32184600)
74. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
75. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881 (Pubitemid 32750970)
76. J. Crook, C. Ludgate, and S. Malone Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 327 333
77. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
78. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
79. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
80. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300 (Pubitemid 27318990)
81. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295 (Pubitemid 351159365)
82. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
83. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
84. M. Roach III, J. Lu, and M.V. Pilepich Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627 (Pubitemid 30317479)
85. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066-73.
86. A.V. D'Amico, B.J. Moran, and M.H. Braccioforte Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease J Clin Oncol 27 2009 3923 3928
87. L.C. Fang, G.S. Merrick, and W.M. Butler High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/ml treated with permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 81 2011 992 996
88. Dattoli M, Wallner K, True L, Bostwick D, Cash J, Sorace R. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol. In press. doi:10.1155/2010/471375.
89. A. Nanda, M.H. Chen, and B.J. Moran Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy Int J Radiat Oncol Biol Phys 76 2010 1439 1444
90. K.E. Hoffman, M.H. Chen, and B.J. Moran Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer Cancer 116 2010 2590 2595
91. S.J. Dibiase, A. Hussain, and R. Kataria Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 81 2011 732 736
92. Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA;303:1046-53.
93. A. Trofimov, P.L. Nguyen, and J.J. Coen Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison Int J Radiat Oncol Biol Phys 69 2007 444 453 (Pubitemid 47380086)
94. C. Vargas, A. Fryer, and C. Mahajan Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 744 751 (Pubitemid 351199706)
95. B. Pickett, J. Kurhanewicz, and J. Pouliot Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level Int J Radiat Oncol Biol Phys 65 2006 65 72
96. Jabbari S, Weinberg VK, Shinohara K, et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys;76:36-42.
97. J.J. Coen, A.L. Zietman, and C.J. Rossi Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis Int J Radiat Oncol Biol Phys 82 2012 e25 e31
98. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508 1513
99. G. Arcangeli, L. Strigari, and S. Arcangeli Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 975 982
100. S.A. Boorjian, R.J. Karnes, and R. Viterbo Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer Cancer 117 2011 2883 2891
101. F. Abdollah, M. Sun, and R. Thuret A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006 Eur Urol 59 2011 88 95
102. S.H. Giordano, Y.F. Kuo, Z. Duan, G.N. Hortobagyi, J. Freeman, and J.S. Goodwin Limits of observational data in determining outcomes from cancer therapy Cancer 112 2008 2456 2466
103. P. Helo, A.M. Cronin, and D.C. Danila Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival Clin Chem 55 2009 765 773
104. M.A. Leversha, J. Han, and Z. Asgari Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer Clin Cancer Res 15 2009 2091 2097
105. K.L. Penney, J.A. Sinnott, and K. Fall mRNA expression signature of Gleason grade predicts lethal prostate cancer J Clin Oncol 29 2011 2391 2396
106. P.J. Bastian, J. Ellinger, L.C. Heukamp, P. Kahl, S.C. Müller, and A. von Rücker Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy Eur Urol 51 2007 665 674 discussion 674 (Pubitemid 46097267)
107. R.J. Karnes, J.C. Cheville, and C.M. Ida The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status Cancer Res 70 2010 8994 9002
108. J. Ellinger, P. Kahl, and J. von der Gathen Global levels of histone modifications predict prostate cancer recurrence Prostate 70 2010 61 69
109. T.C. Stadler, A. Jung, and B. Schlenker Pyrosequencing in uro-oncology: applications in prostate cancer [in German] Urologe A 48 2010 1356 1364
110. C. Jerónimo, P.J. Bastian, and A. Bjartell Epigenetics in prostate cancer: biologic and clinical relevance Eur Urol 60 2011 753 766
111. R.J. Burri, N.N. Stone, P. Unger, and R.G. Stock Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys. 77 2010 1338 1344
112. M.R. Cooperberg, A.J. Vickers, J.M. Broering, P.R. Carroll for the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 2010 5226 5234